Daito Pharmaceutical Co., Ltd. Logo

Daito Pharmaceutical Co., Ltd.

Integrated manufacturer of APIs and finished drugs for generic and OTC markets.

4577 | T

Overview

Corporate Details

ISIN(s):
JP3486150000
LEI:
Country:
Japan
Address:
富山市八日町326番地

Description

Daito Pharmaceutical Co., Ltd. is a manufacturer specializing in the integrated production of pharmaceuticals, from active pharmaceutical ingredients (APIs) to finished formulation products. The company's core activities include the development and supply of APIs, primarily for generic drugs, and the manufacturing of generic and over-the-counter (OTC) medications. Additionally, Daito provides contract manufacturing services for various pharmaceutical products. The company emphasizes a comprehensive quality assurance system to ensure the stable supply of high-quality products to its clients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-08-30 07:38
有価証券報告書-第82期(2023/06/01-2024/05/31)
Japanese 1.3 MB
2024-08-28 09:43
臨時報告書
Japanese 20.4 KB
2024-04-12 09:17
確認書
Japanese 8.2 KB
2024-04-12 09:15
四半期報告書-第82期第3四半期(2023/12/01-2024/02/29)
Japanese 149.0 KB
2024-01-12 08:24
臨時報告書
Japanese 21.7 KB
2024-01-12 08:20
確認書
Japanese 8.2 KB
2024-01-12 08:16
四半期報告書-第82期第2四半期(2023/09/01-2023/11/30)
Japanese 181.1 KB
2023-10-13 04:46
確認書
Japanese 8.2 KB
2023-10-13 04:42
四半期報告書-第82期第1四半期(2023/06/01-2023/08/31)
Japanese 142.7 KB
2023-08-31 07:51
臨時報告書
Japanese 22.9 KB
2023-08-30 04:51
確認書
Japanese 8.2 KB
2023-08-30 04:49
内部統制報告書-第81期(2022/06/01-2023/05/31)
Japanese 22.1 KB
2023-08-30 04:46
有価証券報告書-第81期(2022/06/01-2023/05/31)
Japanese 1.2 MB
2023-04-13 09:15
確認書
Japanese 8.2 KB
2023-04-13 09:12
四半期報告書-第81期第3四半期(2022/12/01-2023/02/28)
Japanese 148.5 KB

Automate Your Workflow. Get a real-time feed of all Daito Pharmaceutical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Daito Pharmaceutical Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Daito Pharmaceutical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.